Kezar Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Business Update
Retrieved on:
Thursday, March 17, 2022
Oncology, Health, Infectious Diseases, Other Health, Pharmaceutical, Biotechnology, Private Securities Litigation Reform Act, Risk, SLE, Biomarker, Degenerative disease, Research, Association, International, Lupus nephritis, Disease, Dialysis, Dermatomyositis, Diagnosis, Immunosuppression, American Association, UPCR, Annual general meeting, International nonproprietary name, U.S. Securities and Exchange Commission, List of life sciences, Respiration, Autoimmunity, Chronic kidney disease, Forward-looking statement, Death, Clinical trial, Pharmacokinetics, Mortality, Myopathy, Kezar Pavilion, AACR, TIS, Inflammation, Disclosure, American Association for Cancer Research, Muscle, Drug discovery, INN, Patient, Total, Cell, PM, Skin, Tumor microenvironment, Proteinuria, Safety, Data collection, COVID-19, Sec61, Pharmaceutical industry, Construction, Vaccine, LN, Polymyositis, Zetomipzomib (KZR-616), KZR-261, Lupus Nephritis, Dermatomyositis and Polymyositis, Inhibition of Protein Secretion, Kezar Life Sciences, ZETOMIPZOMIB (KZR-616), KZR-261, LUPUS NEPHRITIS, DERMATOMYOSITIS AND POLYMYOSITIS, INHIBITION OF PROTEIN SECRETION, KEZAR LIFE SCIENCES
Kezar Life Sciences, Inc ., (Nasdaq: KZR ), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today reported financial results for the fourth quarter and year ended December 31, 2021 and provided a business update.
Key Points:
- Kezar Life Sciences, Inc ., (Nasdaq: KZR ), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today reported financial results for the fourth quarter and year ended December 31, 2021 and provided a business update.
- The MISSION Phase 2 open-label trial in patients with active, proliferative LN reached target enrollment of 20 patients in November 2021.
- Research and development expenses for the fourth quarter of 2021 increased by $1.7 million to $9.8 million compared to $8.1 million in the fourth quarter of 2020.
- General and administrative expenses for the fourth quarter of 2021 increased by $1.3 million to $4.3 million compared to $3.0 million in the fourth quarter of 2020.